Evidence map›Paper›PMID 39286239›Full record

ArticleClinical kidney journal2024

Hydroxychloroquine as an add-on therapy for the induction therapy of MPO-AAV: a retrospective observational cohort study.

Yizi Gong, Ting Meng, Wei Lin, Xueling Hu, Rong Tang, Qi Xiong, Joshua D Ooi, Peter J Eggenhuizen, Jinbiao Chen, Ya-Ou Zhou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yizi GongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Ting MengDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Xueling HuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Rong TangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0001-5619-6047
Qi XiongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Joshua D OoiDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Peter J EggenhuizenCentre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
Jinbiao ChenDepartment of medical records & information, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Ya-Ou ZhouDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Hui LuoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Jia XuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Ning LiuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Ping XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Xiangcheng XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Yong ZhongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0003-2520-0087

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The remission rate of myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients who received standard induction therapy is far from satisfactory. Improving the remission rate of MPO-AAV patients is essential. Hydroxychloroquine (HCQ), one of the classic antimalarial drugs, has been widely used in various autoimmune rheumatic diseases. This retrospective observational cohort study is aimed to evaluate the efficacy and safety of HCQ during induction treatment for MPO-AAV. Methods: The medical records of patients diagnosed with MPO-AAV at Xiangya Hospital, Central South University from January 2021 to September 2023 were collected. They were assigned to the HCQ group or control group according to whether they used HCQ. The patients included were screened by propensity score matching. To evaluate whether MPO-AAV patients benefited from HCQ, we compared the prognosis of the two groups. The adverse effects of HCQ during follow-up were recorded. Results: The composition ratio of complete remission, response and treatment resistance between HCQ group and control group were different statistically ( Conclusions: HCQ together with standard induction treatment may improve the remission rate of MPO-AAV patients, and HCQ had good safety in our study.

Indexed as

ANCA-associated vasculitishydroxychloroquinemyeloperoxidase-AAVremission

Identifiers

PMID39286239
PMCPMC11403311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.